Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248481 | 0.90 | L3MBTL1 (0.36) | TDP1HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL27252284 | 0.89 | HDAC6 (0.39) | TDP1HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL26663164 | 0.85 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL26663905 | 0.84 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL15031625 | 0.82 | MEN1 (0.38) | TDP1HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL10327556 | 0.82 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL3215985 | 0.82 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL3004120 | 0.82 | MEN1 (0.38) | TDP1HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL10327241 | 0.82 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL30380807 | 0.82 | MEN1 (0.38) | TDP1HDAC6HDAC1HDAC2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2023059583-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | TDP1 1293/4885HDAC6 104/4885HDAC1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.